|
| related topics |
| {product, candidate, development} |
| {customer, product, revenue} |
| {loss, insurance, financial} |
| {stock, price, share} |
| {stock, price, operating} |
| {interest, director, officer} |
| {personnel, key, retain} |
| {provision, law, control} |
| {property, intellectual, protect} |
| {product, liability, claim} |
|
|
Factors that May Affect the Future Results of our Business
Our revenue would decline significantly if we lose one or more of our most significant customers, which could have a significant adverse impact on us.
We depend on our senior management, the loss of whom would have an adverse effect on us.
There is no assurance that we will remain listed on an active trading market.
We may not receive approval for our pending patent applications for nutritional supplements, which could enable our competitors to use similar methods and processes.
Our product candidates are at an early stage of development, and if we are not able to successfully develop and commercialize them, we may not generate sufficient revenues to continue our Biotechnology business segment.
We have entered into several transactions with entities controlled by some of our officers and directors, which could pose a conflict of interest.
Our Executive Officers and Directors have majority voting power and may take actions that may not be in the best interest of other stockholders, but in their own interest.
We have a staggered Board of Directors, which could impede an attempt to acquire us or remove our management.
Our product liability insurance may be insufficient to cover possible claims against us.
There is no assurance that we will be able to produce Paclitaxel on a commercial scale.
Our InB:Paxis Pharmaceuticals, Inc. subsidiary uses botanical materials derived from the yew tree, or taxus canadensis, to produce Paclitaxel, a cancer therapy drug. Yew trees are in limited supply. Paxis has formed a joint venture with Chatham Biotec, Ltd. to produce extract and intermediate precursor Paclitaxel from Canadian Taxus trees. We can give no assurance that the joint venture will be successful in producing such Paclitaxel or that we can locate alternate sources of yew trees.
We may not be able to obtain raw materials used in certain of our manufactured products.
Full 10-K form ▸
|
|
| related documents |
| 838879--4/15/2009--AMDL_INC |
| 1436083--7/20/2009--New_Millennium_Products |
| 899866--2/23/2009--ALEXION_PHARMACEUTICALS_INC |
| 1016504--10/14/2008--INTEGRATED_BIOPHARMA_INC |
| 780127--1/4/2008--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 780127--1/7/2009--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 875657--3/16/2010--ULTRALIFE_CORP |
| 1102934--11/27/2007--CABOT_MICROELECTRONICS_CORP |
| 1025362--3/31/2010--GOLDEN_QUEEN_MINING_CO_LTD |
| 1279695--3/28/2008--UNIVERSAL_BIOSENSORS_INC |
| 834365--3/31/2009--BIOLIFE_SOLUTIONS_INC |
| 1123361--3/6/2007--VIASYS_HEALTHCARE_INC |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 875657--3/13/2009--ULTRALIFE_CORP |
| 806517--3/27/2009--PSYCHEMEDICS_CORP |
| 1101026--5/18/2009--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 710597--3/31/2009--AXCESS_INTERNATIONAL_INC/TX |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 38074--5/30/2007--FOREST_LABORATORIES_INC |
| 844161--4/17/2008--CHEROKEE_INC |
| 6281--11/25/2008--ANALOG_DEVICES_INC |
| 886530--3/16/2009--DATATRAK_INTERNATIONAL_INC |
| 764244--4/24/2008--INTERVOICE_INC |
| 884269--3/10/2010--ALPHA_PRO_TECH_LTD |
| 1260968--3/5/2008--MARLIN_BUSINESS_SERVICES_CORP |
| 1092791--7/28/2010--PACIFIC_LAND_&_COFFEE_CORP |
| 6281--11/24/2009--ANALOG_DEVICES_INC |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 780127--1/12/2006--SYNOVIS_LIFE_TECHNOLOGIES__INC |
|